In ₹ Crore except Per Share Latest Annual	3BBLACKBIO FY25	HEALTHX FY26	SURAKSHA FY26	KRSNAA FY26	Peer Average
Valuation — at last close
P/E	—	754.59×	51.71×	◆ 15.91×	274.07×
P/B	—	◆ 1.39×	6.80×	1.65×	3.28×
EV/EBITDA	—	◆ -19.27×	17.17×	8.44×	2.11×
Market Cap	—	₹888 Cr	₹1,664 Cr	₹1,615 Cr	₹1,389 Cr
Growth
Revenue CAGR 3Y	—	8.26%	—	◆ 16.63%	12.45%
Revenue CAGR 5Y	—	19.20%	—	—	19.20%
Net Income CAGR 3Y	—	—	—	17.76%	17.76%
Revenue YoY (latest Q)	—	◆ 49.73%	20.75%	22.05%	30.84%
Net Income YoY (latest Q)	—	-92.53%	◆ 40.00%	-19.34%	-23.96%
Profitability
EBITDA Margin	◆ 55.07%	-3.95%	30.73%	27.42%	18.07% +205%
Net Income Margin	◆ 52.53%	-0.11%	10.12%	13.13%	7.71% +581%
Return on Common Equity	◆ 19.00%	0.18%	14.11%	10.89%	8.39% +126%
Return on Capital Employed	◆ 19.15%	—	15.88%	9.62%	12.75% +50%
Return on Assets	◆ 17.39%	-0.15%	8.04%	6.53%	4.81% +262%
Credit & Quality
Total Debt/Equity	◆ 0.00×	0.03×	0.01×	0.55×	0.20× -100%
Interest Coverage	◆ 506.18×	-75.12×	4.30×	3.53×	-22.43× +2357%
Scale — latest FY
Revenue / Total Income	₹90.5 Cr	₹1,319 Cr	₹310 Cr	₹773 Cr	₹801 Cr -89%
Net Income	₹47.6 Cr	−₹1.4 Cr	₹31.4 Cr	₹101 Cr	₹43.8 Cr +9%
Total Assets	₹297 Cr	₹936 Cr	₹448 Cr	₹1,824 Cr	₹1,069 Cr -72%
EPS	—	₹0.37	₹6.18	₹31.3	₹12.62
Book Value per Share	—	₹201.47	₹47.01	₹302.23	₹183.57

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.